Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer Journal Article
| Author: | Saltz, L. |
| Article Title: | Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer |
| Abstract: | Irinotecan (Camptosar) is a topoisomerase I inhibitor with demonstrated antitumor activity against a wide variety of malignancies. Phase II studies have shown that this agent has significant single-agent activity against both chemotherapy-naive and fluorouracil (5-FU)-refractory colorectal cancer. Phase III studies now indicate that irinotecan/5-FU/leucovorin combinations have antitumor activity superior to standard 5-FU/ leucovorin regimens alone. These irinotecan-based combinations are now entering clinical trials for the adjuvant treatment of resected stage III colon cancer. It is hypothesized that the superior antitumor activity of these irinotecan-based combinations seen in the metastatic setting will translate into improved survival and increased cure rates in these earlier-stage patients. |
| Keywords: | survival; treatment outcome; survival analysis; clinical trial; review; fluorouracil; chemotherapy, adjuvant; antineoplastic agent; metastasis; controlled clinical trial; phase 2 clinical trial; randomized controlled trial; antineoplastic combined chemotherapy protocols; camptothecin; irinotecan; colorectal neoplasms; randomized controlled trials; colorectal tumor; folinic acid; adjuvant chemotherapy; neoplasm metastasis; drug derivative; phase 3 clinical trial; leucovorin; clinical trials, phase ii; clinical trials, phase iii; humans; human |
| Journal Title: | Oncology (Norwalk) |
| Volume: | 14 |
| Issue: | 12 Suppl. 14 |
| ISSN: | 0890-9091 |
| Publisher: | C M P Medica LLC * The Oncology Group |
| Date Published: | 2000-12-01 |
| Start Page: | 47 |
| End Page: | 50 |
| Language: | English |
| PUBMED: | 11200149 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 18 November 2015 -- Source: Scopus |
